Related Experiment Video
Updated: May 26, 2026
13:42
Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
Published on: March 8, 2013
Autoantibodies in heart failure and cardiac dysfunction.
Ziya Kaya1, Christoph Leib, Hugo A Katus
1Department of Internal Medicine III, University of Heidelberg, Germany. ziya.kaya@med.uni-heidelberg.de
Circulation Research
|January 7, 2012
Summary
This review explores circulating autoantibodies in human heart failure, highlighting their role in disease progression and discussing potential immune system involvement. Therapeutic strategies targeting the humoral immune system are also examined.
Area of Science:
- Immunology
- Cardiology
- Pathophysiology
Background:
- Heart failure is a complex disease with high mortality.
- Circulating autoantibodies, including heart-specific ones, are implicated in heart failure progression.
- Mechanisms linking autoantibodies to autoimmune responses and the innate immune system's role are under investigation.
Purpose of the Study:
- To review current literature on autoantibodies associated with human heart failure.
- To present evidence from clinical and animal studies on the relevance of autoantibodies in heart failure.
- To explore molecular and cellular mechanisms involved in autoantibody-induced heart failure.
Main Methods:
- Literature review of clinical and animal studies.
- Analysis of molecular and cellular mechanisms.
- Critical discussion of therapeutic interventions.
Main Results:
- Autoantibodies are demonstrably present and play a pathophysiological role in heart failure.
- Evidence suggests a link between the innate immune system and auto-reactive antibody generation.
- Intravenous immunoglobulins and immunoadsorption show potential therapeutic benefits.
Conclusions:
- Circulating autoantibodies are significant factors in human heart failure.
- Further research is needed to fully understand the mechanisms of autoantibody induction and perpetuation.
- Targeting the humoral immune system offers promising therapeutic avenues for heart failure.
Related Concept Videos
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:23Rheumatic Heart Disease I: Introduction
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...